US Patent Issued to BIONOXX on Feb. 11 for "Oncolytic virus improved in safety and anticancer effect" (South Korean Inventors)

ALEXANDRIA, Va., Feb. 12 -- United States Patent no. 12,220,437, issued on Feb. 11, was assigned to BIONOXX INC. (Seongnam-si, South Korea).

"Oncolytic virus improved in safety and anticancer effect" was invented by Taeho Hwang (Yangsan-si, South Korea) and Mong Cho (Yangsan-si, South Korea).

According to the abstract* released by the U.S. Patent & Trademark Office: "A recombinant oncolytic virus with improved safety and anticancer effect and a use thereof are disclosed. The recombinant oncolytic virus is obtained by inserting an HSV-TK fragment-encoding gene into a TK gene region to delete TK of Vaccinia virus. The oncolytic virus expresses an HSV-TK fragment to phosphorylate GCV so that cancer cells infected with the oncolytic virus and...